Delix Therapeutics

📍 Boston, United States🗓 Founded 2019👥 37 employees💰 Last funded Nov 2021
Biotechnology🌐 delixtherapeutics.com
Website LinkedIn
Delix Therapeutics is applying modern tools of pharmaceutical development to some of natures most ancient therapies, psychedelics. Through its discovery platform, Delix has identified a new class of non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles. Delix is rapidly advancing these psychoplastogen compounds through preclinical and clinical development, with the goal of one day alleviating mental suffering through its FDA-approved, take-home medicines.
5
Total investors
5
Early stage
0
Mid stage
0
Late stage
2019
Founded

Investors

5 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
5
Investor activity2018–2021 · investors recorded per year
20181201912020120212
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Delix Therapeutics?
Delix Therapeutics has 5 investors on record on gritt.io, including 5 early-stage backers.
When did Delix Therapeutics last raise funding?
The most recent investment in Delix Therapeutics recorded on gritt.io was in November 2021.
When was Delix Therapeutics founded?
Delix Therapeutics was founded in 2019.
What industry is Delix Therapeutics in?
Delix Therapeutics operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Delix Therapeutics based?
Delix Therapeutics is headquartered in Boston, United States.